- Home
- HTOO vs KZIA Comparison
HTOO vs KZIA Comparison
Compare HTOO & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTOO
- KZIA
- Stock Information
- Founded
- HTOO 2020
- KZIA 1994
- Country
- HTOO Ireland
- KZIA Australia
- Employees
- HTOO N/A
- KZIA N/A
- Industry
- HTOO Natural Gas Distribution
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- HTOO Utilities
- KZIA Health Care
- Exchange
- HTOO Nasdaq
- KZIA Nasdaq
- Market Cap
- HTOO 12.3M
- KZIA 12.6M
- IPO Year
- HTOO N/A
- KZIA 1999
- Fundamental
- Price
- HTOO $0.38
- KZIA $4.62
- Analyst Decision
- HTOO Strong Buy
- KZIA Strong Buy
- Analyst Count
- HTOO 1
- KZIA 1
- Target Price
- HTOO $3.50
- KZIA $20.00
- AVG Volume (30 Days)
- HTOO 501.4K
- KZIA 148.4K
- Earning Date
- HTOO 12-02-2024
- KZIA 11-19-2024
- Dividend Yield
- HTOO N/A
- KZIA N/A
- EPS Growth
- HTOO N/A
- KZIA N/A
- EPS
- HTOO N/A
- KZIA N/A
- Revenue
- HTOO $4,580,524.00
- KZIA $382.00
- Revenue This Year
- HTOO $440.97
- KZIA $4,053,954.00
- Revenue Next Year
- HTOO $214.20
- KZIA N/A
- P/E Ratio
- HTOO N/A
- KZIA N/A
- Revenue Growth
- HTOO N/A
- KZIA N/A
- 52 Week Low
- HTOO $0.32
- KZIA $1.90
- 52 Week High
- HTOO $4.65
- KZIA $15.80
- Technical
- Relative Strength Index (RSI)
- HTOO 39.02
- KZIA 50.25
- Support Level
- HTOO $0.32
- KZIA $5.21
- Resistance Level
- HTOO $0.81
- KZIA $6.88
- Average True Range (ATR)
- HTOO 0.10
- KZIA 0.76
- MACD
- HTOO -0.02
- KZIA -0.11
- Stochastic Oscillator
- HTOO 18.37
- KZIA 22.80
About HTOO Fusion Fuel Green PLC
Fusion Fuel Green PLC is a company that has developed a Green Hydrogen production technology. It is focused on generating cost-effective and competitively priced Green Hydrogen.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.